Evidence map›Paper›PMID 36029651›Full record

ArticleESMO open2022

Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A.

D V T Catenacci, Y-K Kang, H H Yoon, B Y Shim, S T Kim, D-Y Oh, A I Spira, S V Ulahannan, E J Avery, P M Boland and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Review
  4. Advancements in targeted therapy for gastric cancer.Therapeutic advances in gastroenterology · 2026
    Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. HER2-targeted therapies beyond breast cancer - an update.Nature reviews. Clinical oncology · 2024
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 20 institutions in 6 countries.

D V T CatenacciDepartment of Medicine, The University of Chicago Medical Centre, Chicago, USA. Electronic address: DocCatenacci@catenacciconsulting.com.
Y-K KangDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
H H YoonDivision of Medical Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, USA.
B Y ShimMedical Oncology, The Catholic University of Korea St. Vincent's Hospital, Suwon, Republic of Korea.
S T KimHematology and Oncology, Samsung Medical Center, Seoul, Republic of Korea.
D-Y OhInternal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, Republic of Korea.
A I SpiraVirginia Cancer Specialists Research Institute, Fairfax, USA.
S V UlahannanUniversity of Oklahoma Health Sciences Center - Stephenson Cancer Center, Oklahoma City, USA.
E J AveryDivision of Hematology and Oncology, Nebraska Hematology-Oncology, Lincoln, USA.
P M BolandDivision of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, USA.
J ChaoDepartment of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, USA.
H C ChungDepartment of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
F GardnerMedical Oncology, Florida Cancer Specialists, Cape Coral, USA.
S J KlempnerMass General Hospital Cancer Center, Massachusetts General Hospital, Boston, USA.
K-W LeeDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam.
S C OhOncology, Korea University Guro Hospital, Seoul, Republic of Korea.
J PegueroMedical Oncology, Oncology Consultants, Houston, USA.
M B SonbolInternal Medicine Department, Mayo Clinic Cancer Center, Phoenix, USA.
L ShenDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China.
M MoehlerJohannes-Gutenberg University, Mainz, Germany.
J SunMacroGenics, Inc., Rockville, USA.
D LiMacroGenics, Inc., Rockville, USA.
M K RosalesMacroGenics, Inc., Rockville, USA.
H ParkDepartment of Medicine, Washington University School of Medicine, St. Louis, USA.
MacroGenics (United States) · USCity of Hope · USFlorida Cancer Specialists & Research Institute · USHematology Oncology Consultants · USJohannes Gutenberg University Mainz · DEKorea University Medical Center · KRMassachusetts General Hospital · USMayo Clinic · USMayo Clinic in Florida · USNational University College · PRNebraska Hematology-Oncology · USPeking University Cancer Hospital · CNRutgers Cancer Institute · USSamsung Medical Center · KRSeoul National University Hospital · KRThe Catholic University of Korea St. Vincent's Hospital · KRUlsan College · KRUniversity of Chicago Medical Center · USUniversity of Oklahoma Health Sciences Center · USVirginia Cancer Specialists · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHuman epidermal growth factor receptor 2 (HER2)-positive metastatic gastric and gastroesophageal adenocarcinoma (GEA) is globally treated with chemotherapy plus trastuzumab. Novel therapeutic strategies strive to not only optimize efficacy, but also limit toxicities. In MAHOGANY cohort A, margetuximab, an Fc-engineered, anti-HER2 monoclonal antibody (mAb) was combined with retifanlimab, an anti-programmed cell death protein 1 mAb, in the first-line HER2-positive/programmed death-ligand 1 (PD-L1)-positive GEA. PATIENTS AND

methodsMAHOGANY cohort A part 1 is a single-arm trial to evaluate margetuximab plus retifanlimab in patients with HER2 immunohistochemistry 3+, PD-L1-positive (combined positive score ≥1%), and non-microsatellite instability-high tumors. Primary objectives for cohort A were safety/tolerability and the confirmed objective response rate (ORR).

resultsAs of 3 August 2021, 43 patients were enrolled and received margetuximab/retifanlimab. Nine grade 3 treatment-related adverse events (TRAEs) were reported in eight (18.6%) patients and eight serious TRAEs in seven (16.3%) patients. There were no grade 4/5 TRAEs. Three patients discontinued margetuximab/retifanlimab because of immune-related adverse events. The ORR by independent assessment was 53% [21/40 (95% confidence interval (CI) 36.1-68.5)], with a median duration of response of 10.3 months (95% CI 4.6-not evaluable); disease control rate was 73% [29/40 (95% CI 56.1-85.4)]. The study sponsor discontinued the study in advance of the planned enrollment when it became apparent that the study design would no longer meet the requirements for drug approval because of recent advances in the treatment of GEA.

conclusionsThe chemotherapy-free regimen of combined margetuximab/retifanlimab as first-line treatment in double biomarker-selected patients demonstrated a favorable toxicity profile compared with historical outcomes using chemotherapy plus trastuzumab. The ORR observed in this study compares favorably versus ORR observed with other chemotherapy-free approaches.

Indexed as

AdenocarcinomaStomach NeoplasmsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedB7-H1 AntigenHumansImmune Checkpoint InhibitorsTrastuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedB7-H1 AntigenCD274 protein, humanImmune Checkpoint InhibitorsmargetuximabTrastuzumabfirst-line therapyhuman epidermal growth factor receptor 2margetuximabmetastatic gastroesophageal adenocarcinomaprogrammed death-ligand 1retifanlimab

Identifiers

PMID36029651
PMCPMC9588876
OpenAlexW4293200662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.